| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-Valine-13C5 has no independent pharmacological target as it is a stable isotope tracer, not a therapeutic drug. L-Valine itself is an essential amino acid that serves as a substrate for protein synthesis and is metabolized via the branched-chain amino acid degradation pathway. Valine is involved in nitrogen metabolism and serves as an energy source in muscle tissue.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As an isotopic tracer, L-Valine-13C5 is not tested for in vitro pharmacological activity. The non-labeled L-valine demonstrates biological activity including involvement in protein synthesis, induction of lipid peroxidation, and accumulation of malondialdehyde in certain contexts. The 13C-labeled version is used to trace these metabolic processes rather than to exert a pharmacological effect. |
| ln Vivo |
L-Valine-13C5 has no in vivo pharmacological activity as a therapeutic agent. It is administered to animals or incorporated into cell culture media as a stable isotope tracer to study valine metabolism, protein synthesis rates, and energy metabolism. The compound is metabolized identically to natural valine, enabling quantification of metabolic fluxes using mass spectrometry detection of the 13C label.
|
| Enzyme Assay |
For in vitro tracer experiments using L-Valine-13C5, the compound is dissolved in culture media or buffer at desired concentrations (e.g., replacing natural valine in defined media). Cells are cultured in the labeled medium for specified time periods (0, 6, 12, 24, 48 hours). Cells are harvested, lysed, and proteins are extracted. Following protein hydrolysis, amino acids are derivatized and analyzed by LC-MS or GC-MS to determine the incorporation of 13C-labeled valine into cellular proteins.
|
| Cell Assay |
Cells are grown in standard medium until reaching desired confluence. The medium is then replaced with medium containing L-Valine-13C5 at a defined concentration (typically replacing all natural valine in the medium, e.g., 0.4-0.8 mM). Cultures are incubated at 37degC in 5% CO2 for labeling periods ranging from 1 to 72 hours. At each time point, cells are collected, washed with PBS, and lysed in RIPA buffer containing protease inhibitors. Protein concentration is measured, and samples are processed for LC-MS analysis.
|
| Animal Protocol |
For in vivo metabolic tracer studies, L-Valine-13C5 is administered to rodents via intravenous injection, intraperitoneal injection, or oral gavage at doses determined from preliminary studies (e.g., 50-200 mg/kg). Blood samples are collected at multiple time points (e.g., 0, 5, 15, 30, 60, 120 minutes). Tissues (liver, muscle, brain, plasma) are harvested, and amino acids are extracted. 13C enrichment is measured by LC-MS/MS or GC-MS to trace valine metabolism and protein synthesis rates.
|
| ADME/Pharmacokinetics |
L-Valine-13C5 is a stable isotope-labeled tracer and is not a therapeutic drug; therefore, no PK parameters are established for it. When administered, the 13C-labeled valine follows the same metabolic pathways as natural valine. Valine is an essential amino acid absorbed in the small intestine, distributed to tissues via the bloodstream, and metabolized in the liver and muscle. Excess valine is deaminated and the carbon skeleton enters the TCA cycle.
|
| Toxicity/Toxicokinetics |
L-Valine is a naturally occurring essential amino acid with low toxicity. The LD50 of valine in rats is >5,000 mg/kg. At high doses, valine may cause competitive inhibition of other branched-chain amino acids. The 13C-labeled version is chemically identical to natural valine and exhibits the same safety profile. Standard laboratory safety precautions apply. No toxicological concerns specific to the 13C label have been identified.
|
| References | |
| Additional Infomation |
L-Valine-13C5 is not a drug but a stable isotope-labeled research reagent. It has no approved drug status, no clinical trial history, and is not intended for human therapeutic use. It is exclusively used as a quantitative tracer in drug development processes, metabolic studies, and protein synthesis research. The compound is available in high isotopic enrichment (≥95% purity, ≥99 atom% 13C) for mass spectrometry and NMR applications.
|
| Molecular Formula |
C5H11NO2
|
|---|---|
| Molecular Weight |
122.109615564346
|
| Exact Mass |
122.095
|
| CAS # |
55443-52-2
|
| Related CAS # |
L-Valine;72-18-4
|
| PubChem CID |
117064718
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
90.4
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[13CH3][13CH]([13CH3])[13C@@H]([13C](=O)O)N
|
| InChi Key |
KZSNJWFQEVHDMF-JRGPAWSWSA-N
|
| InChi Code |
InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1/i1+1,2+1,3+1,4+1,5+1
|
| Chemical Name |
(2S)-2-amino-3-(113C)methyl(1,2,3,4-13C4)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (409.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.1893 mL | 40.9467 mL | 81.8934 mL | |
| 5 mM | 1.6379 mL | 8.1893 mL | 16.3787 mL | |
| 10 mM | 0.8189 mL | 4.0947 mL | 8.1893 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
